Role of Omeprazole Dosage and Cytochrome P450 2C19 Genotype in Patients Receiving Omeprazole-Amoxicillin Dual Therapy for Helicobacter pylori Eradication

被引:42
作者
Yang, Jyh-Chin [2 ,3 ]
Wang, Hong-Long [5 ]
Chern, Herng-Der [6 ]
Shun, Chia-Tung [4 ]
Lin, Bor-Ru [2 ]
Lin, Chun-Jung [1 ]
Wang, Teh-Hong [2 ]
机构
[1] Natl Taiwan Univ, Coll Med, Sch Pharm, Taipei 100, Taiwan
[2] Natl Taiwan Univ Hosp & Coll Med, Dept Internal Med, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp & Coll Med, Grad Inst Clin Med, Taipei, Taiwan
[4] Natl Taiwan Univ, Dept Forens Med & Pathol, Taipei 100, Taiwan
[5] Natl Taipei Univ, Dept Stat, Taipei, Taiwan
[6] Ctr Drug Evaluat, Taipei, Taiwan
来源
PHARMACOTHERAPY | 2011年 / 31卷 / 03期
关键词
Helicobacter pylori; duodenal ulcer; cytochrome P450; CYP; CYP2C19; genotype; omeprazole; amoxicillin; proton pump inhibitor; PPI; ANTIMICROBIAL RESISTANCE; ANTIBIOTIC-RESISTANCE; TRIPLE THERAPY; INFECTION; CLARITHROMYCIN; METRONIDAZOLE; POLYMORPHISM; RABEPRAZOLE; METABOLISM; FAILURE;
D O I
10.1592/phco.31.3.227
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To determine the factors that may influence Helicobacter pylon eradication in patients receiving omeprazole-amoxicillin dual therapy Design. Prospective, randomized study Setting. University-affiliated hospital in Taiwan. Patients. A total of 128 adults (age range 20-75 yrs) with H. pylori positive duodenal ulcer were enrolled; 121 completed the final evaluation. Intervention. Patients were randomly assigned to one of four omeprazole-amoxicillin treatment groups, with each treatment administered for 2 weeks: O2A2 group (33 patients)-omeprazole 20 mg twice/day plus amoxicillin 500 mg 4 times/day; O2A1 group (32 patients) omeprazole 20 mg twice/day plus amoxicillin 250 mg 4 times/day; O1A2 group (32 patients) omeprazole 20 mg once/day plus amoxicillin 500 mg 4 times/day; and O1A1 group (31 patients) omeprazole 20 mg once/day plus amoxicillin 250 mg 4 times/day. Measurements and Main Results. Data were collected on H. pylon status, histologic parameters, antibiotic resistance, intragastric pH, cytochrome P450 (CYP) 2C19 genotype, and adverse reactions. The intent-to-treat cure rates (95% confidence interval [CID in groups O2A2, O2A1, O1A2, and O1A1 were 76% (95% CI 59-87%), 72% (95% CI 54-84%), 50% (95% CI 34-66%) and 52% (95% CI 35-68%), respectively. Eradication of H. pylori infection was statistically significantly dependent on omeprazole dosage, CYP2C19 genotype, age, gastritis status, and H. pylori density. All CYP2C19 poor metabolizers were cured, whereas the H. pylon cure rate in CYP2C19 extensive metabolizers varied from 44-76% in the different treatment groups. Eradication of H. pylon was favored in the omeprazole higher dose groups versus the lower dose groups (79% vs 53%, p=0.004). No secondary antibiotic resistance was found. Thirty-seven (95%) of 39 patients who failed with the initial treatment were cured by subsequent antibiotic susceptibility driven proton pump inhibitor based triple therapy. Conclusion. Provided a maintenance dose of amoxicillin is given every 6 hours, eradication of H. pylon infection was significantly dependent on omeprazole dosage, CYP2C19 genotype, age, gastritis status, and H. pylon density.
引用
收藏
页码:227 / 238
页数:12
相关论文
共 36 条
[1]   DOUBLE-BLIND TRIAL OF OMEPRAZOLE AND AMOXICILLIN TO CURE HELICOBACTER-PYLORI INFECTION IN PATIENTS WITH DUODENAL-ULCERS [J].
BAYERDORFFER, E ;
MIEHLKE, S ;
MANNES, GA ;
SOMMER, A ;
HOCHTER, W ;
WEINGART, J ;
HELDWEIN, W ;
KLANN, H ;
SIMON, T ;
SCHMITT, W ;
BASTLEIN, E ;
EIMILLER, A ;
HATZ, R ;
LEHN, N ;
DIRSCHEDL, P ;
STOLTE, M .
GASTROENTEROLOGY, 1995, 108 (05) :1412-1417
[2]   BACTERICIDAL AND MORPHOLOGICAL EFFECTS OF AMOXICILLIN ON HELICOBACTER-PYLORI [J].
BERRY, V ;
JENNINGS, K ;
WOODNUTT, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (08) :1859-1861
[3]  
DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594
[4]  
DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419
[5]   Classification and grading of gastritis - The updated Sydney System [J].
Dixon, MF ;
Genta, RM ;
Yardley, JH ;
Correa, P ;
Batts, KP ;
Dahms, BB ;
Filipe, MI ;
Haggitt, RC ;
Haot, J ;
Hui, PK ;
Lechago, J ;
Lewin, K ;
Offerhaus, JA ;
Price, AB ;
Riddell, RH ;
Sipponen, P ;
Solcia, E ;
Watanabe, H .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1996, 20 (10) :1161-1181
[6]   Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy -: A meta-analytical approach [J].
Dore, MP ;
Leandro, G ;
Realdi, G ;
Sepulveda, AR ;
Graham, DY .
DIGESTIVE DISEASES AND SCIENCES, 2000, 45 (01) :68-76
[7]   The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: Relevance to the treatment of Helicobacter pylori infection [J].
Erah, PO ;
Goddard, AF ;
Barrett, DA ;
Shaw, PN ;
Spiller, RC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (01) :5-12
[8]   Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin [J].
Furuta, T ;
Shirai, N ;
Takashima, M ;
Xiao, F ;
Hanai, H ;
Nakagawa, K ;
Sugimura, H ;
Ohashi, K ;
Ishizaki, T .
PHARMACOGENETICS, 2001, 11 (04) :341-348
[9]   European Multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori [J].
Glupczynski, Y ;
Mégraud, F ;
Lopez-Brea, M ;
Andersen, LP .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2001, 20 (11) :820-823
[10]   Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations [J].
Goldstein, JA ;
Ishizaki, T ;
Chiba, K ;
deMorais, SMF ;
Bell, D ;
Krahn, PM ;
Evans, DAP .
PHARMACOGENETICS, 1997, 7 (01) :59-64